ALPHA TEKNOVA, INC. (TKNO) Spending and interest coverage
- R&D / revenue · 12 months: Value 5.10%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 6.74%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 5.10% | Research and development expense / revenue. Period ending 2026-06-30. $2.23M ÷ $43.70M × 100 ≈ 5.10% |
| Stock-based compensation / revenue · 12 months | 6.74% | Share-based compensation / revenue. Period ending 2026-06-30. $2.94M ÷ $43.70M × 100 ≈ 6.74% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 2.23M USD | Research and Development Expense |
| Revenue | 43.70M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 2.94M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -15.81M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.23M | $43.70M | $2.94M | $-15.81M | (m) | 5.10% | 6.74% | (m) | (m) |
| 2026-03-31 | $2.25M | $41.80M | $3.27M | $-16.31M | (m) | 5.39% | 7.83% | (m) | (m) |
| 2025-12-31 | $2.20M | $40.52M | $3.43M | $-16.98M | (m) | 5.42% | 8.46% | (m) | (m) |
| 2025-09-30 | $2.27M | $39.80M | $3.42M | $-18.00M | (m) | 5.70% | 8.59% | (m) | (m) |
| 2025-06-30 | $2.35M | $38.92M | $3.33M | $-21.41M | (m) | 6.05% | 8.55% | (m) | (m) |
| 2025-03-31 | $2.45M | $38.25M | $3.21M | $-23.12M | (m) | 6.41% | 8.39% | (m) | (m) |
| 2024-12-31 | $2.76M | $37.74M | $3.67M | $-26.15M | (m) | 7.31% | 9.71% | (m) | (m) |
| 2024-09-30 | $3.48M | $36.35M | $3.92M | $-31.38M | (m) | 9.56% | 10.79% | (m) | (m) |
| 2024-06-30 | $4.25M | $34.94M | $4.20M | $-32.71M | (m) | 12.15% | 12.01% | (m) | (m) |
| 2024-03-31 | $5.03M | $36.85M | $4.43M | $-34.60M | (m) | 13.65% | 12.03% | (m) | (m) |
| 2023-12-31 | $5.57M | $36.68M | $4.14M | $-35.56M | (m) | 15.18% | 11.28% | (m) | (m) |
| 2023-09-30 | $6.13M | $36.71M | $4.14M | $-38.94M | (m) | 16.69% | 11.27% | (m) | (m) |
| 2023-06-30 | $6.65M | $39.23M | $4.07M | $-53.13M | (m) | 16.96% | 10.37% | (m) | (m) |
| 2023-03-31 | $7.12M | $39.39M | $3.93M | $-52.76M | (m) | 18.07% | 9.99% | (m) | (m) |
| 2022-12-31 | $7.74M | $41.42M | $3.71M | $-49.66M | (m) | 18.68% | 8.96% | (m) | (m) |
| 2022-09-30 | $7.26M | $43.64M | $3.31M | $-40.19M | (m) | 16.63% | 7.59% | (m) | (m) |
| 2022-06-30 | $6.71M | $42.34M | $2.79M | $-21.12M | (m) | 15.84% | 6.58% | (m) | (m) |
| 2022-03-31 | $5.63M | $38.96M | $2.15M | $-17.02M | (m) | 14.44% | 5.53% | (m) | (m) |
| 2021-12-31 | $4.31M | $36.89M | $1.55M | $-12.01M | (m) | 11.69% | 4.20% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $1.51M | $31.30M | $300.00K | $4.66M | (m) | 4.82% | 0.96% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |